L3VLUP
ProSign in

ROIV · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ROIVVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ROIV
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterROIVVRTX
Q3 2020none listed holders, n.a.31 holders, $21.9bn
Q4 2020none listed holders, n.a.30 holders, $18.4bn
Q1 2021none listed holders, n.a.31 holders, $15.4bn
Q2 2021none listed holders, n.a.30 holders, $12.7bn
Q3 2021none listed holders, n.a.35 holders, $10.1bn
Q4 20211 holders, $889m28 holders, $12.4bn
Q1 20221 holders, $436m23 holders, $16.1bn
Q2 20221 holders, $359m25 holders, $18.1bn
Q3 20222 holders, $292m22 holders, $18.4bn
Q4 20223 holders, $829m28 holders, $18.4bn
Q1 20236 holders, $715m26 holders, $21.4bn
Q2 20238 holders, $1.0bn27 holders, $24.7bn
Q3 20238 holders, $1.7bn33 holders, $24.3bn
Q4 20236 holders, $1.5bn32 holders, $28.6bn
Q1 20246 holders, $912m31 holders, $29.8bn
Q2 20248 holders, $1.4bn29 holders, $33.4bn
Q3 20248 holders, $1.4bn27 holders, $33.5bn
Q4 20248 holders, $1.3bn26 holders, $28.5bn
Q1 20257 holders, $1.1bn21 holders, $35.4bn
Q2 20259 holders, $1.2bn21 holders, $32.3bn
Q3 202511 holders, $1.5bn22 holders, $25.9bn
Q4 202514 holders, $1.9bn26 holders, $31.8bn
Q1 202614 holders, $3.3bn25 holders, $31.8bn
Q2 202615 holders, $4.5bn26 holders, $34.6bn
ROIV

Roivant Sciences LTD

Holders
14
Reported value
$3.3bn
Buyers
18
Sellers
15

Breadth +3 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
25
Reported value
$31.8bn
Buyers
17
Sellers
21

Breadth -4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 33 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ROIV (8)

AQR Capital Management LLC, Brevan Howard Capital Management LP, Farallon Capital Management LLC, Greenlight Capital, Maverick Capital Ltd, PDT Partners LLC, Viking Global Investors LP, Winton Group Ltd

Only VRTX (19)

Acadian Asset Management LLC, AllianceBernstein LP, Arrowstreet Capital LP, Baillie Gifford & Co, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., ExodusPoint Capital Management LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, Two Sigma Investments LP, Walleye Capital LLC, Wellington Management Group LLP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →